Immunome Inc. Insider Reports Securities Transaction

TL;DR

Immunome Inc. insider Clay B. Siegall filed a Form 4 on 3/31/26 for transactions on 3/27/26.

AI Summary

On March 27, 2026, Clay B. Siegall, a reporting person for Immunome Inc., reported a change in beneficial ownership of securities. The filing details transactions related to Immunome Inc. stock, with specific details on the nature of the transaction and the number of shares involved not fully disclosed in this excerpt.

Why It Matters

Insider transactions can signal management's confidence or concerns about the company's future performance, potentially influencing investor sentiment.

Risk Assessment

Risk Level: medium — Form 4 filings indicate changes in insider holdings, which can be a leading indicator of future stock performance, but the specific nature of the transaction is not detailed here.

Key Players & Entities

• Immunome Inc. (company) — Issuer
• Clay B. Siegall (person) — Reporting Person
• 2026-03-27 (date) — Period of Report
• 2026-03-31 (date) — Filing Date

FAQ

Key Financial Figures

• $19 — se price for the transaction report was $19.67, and the range of prices were betwee
• $19.63 — 7, and the range of prices were between $19.63 and $19.70, inclusive. Upon request by

Filing Documents

• form4-03312026_110335.html (4)
• form4-03312026_110335.xml (4) — 4KB
• 0001167496-26-000003.txt ( ) — 5KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * SIEGALL CLAY B (Last) (First) (Middle) C/O IMMUNOME, INC. 18702 N. CREEK PARKWAY, SUITE 100 (Street) BOTHELL WASHINGTON 98011 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol Immunome Inc. [ IMNM ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) President and CEO 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/27/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/27/2026 P 25,450 A $ 19.67 (1) 690,704 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. The weighted average purchase price for the transaction report was $19.67, and the range of prices were between $19.63 and $19.70, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. /s/ Sandra Stoneman, Attorney-in-Fact 03/31/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR